Đánh giá hiệu quả điều trị của phác đồ ARV TDF+3TC+DTG trên bệnh nhân HIV/AIDS tại Bệnh viện Đa khoa Đống Đa 2020-2021

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Xuân Toản Lê, Kim Thư Nguyễn, Bá Hiền Phạm

Ngôn ngữ: vie

Ký hiệu phân loại: 362.19697920081 Physical illness

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2022

Mô tả vật lý: 164-168

Bộ sưu tập: Metadata

ID: 498821

Thêm vào giỏ

Tóm tắt
Chủ đề

HIV/AIDs infection is a burden of disease for patients and their families and society as a whole. Anti-retroviral drugs (ARV) are the optimal treatment for HIV/AIDS patients. The TDF+3TC+DTG regimen was newly approved and recommended by MOH in Vietnam. Objective: To study the effectiveness and side effects of TDF + 3TC + DTG regimen in HIV/AIDS patients at Dong Da General Hospital. Subjects: The study involved 61 patients diagnosed with HIV/AIDS and treated with the TDF+3TC+DTG regimen followed for a full 24 weeks, between February 202 and June 2021. Method: retrospective cross-description study. Results: Weight, BMI and CD4 count increases statistically (p<
0.05) at the time after 24 weeks of treatment. 45/61 (73.8%) of patients reached the under detective threshold virus level. Adherence to treatment is associated with viral load treatment result (OR=2.32 CI95% 0.21-8.643, p<
0.05). Conclusion: The TDF+3TC+DTG ARV drug regimen has a good treatment effect in patients with HIV/AIDS (weight, CD4 increases after 24 weeks of treatment and the virus is inhibited at a high rate). The group of patients who adhered to good treatment had a maximum of 2.32 times the ability to suppress the virus with a group that adhered to bad treatment.Nhiễm HIV/AIDS là gánh nặng về bệnh tật cho người bệnh và gia đình bệnh nhân cũng như toàn xã hội. Điều trị bằng các thuốc (ARV-anti retroviral drugs) đang là biện pháp điều trị tối ưu cho nhóm bệnh nhân nhiễm HIV/AIDS. Bộ Y tế Việt Nam mới đây phê chuẩn và khuyến cáo sử dụng phác đồ TDF+3TC+DTG. Mục tiêu: Đánh giá hiệu quả điều trị và tác dụng không mong muốn của phác đồ TDF + 3TC + DTG trên bệnh nhân HIV/AIDS tại bệnh viện đa khoa Đống Đa. Đối tượng: Nghiên cứu trên 61 bệnh nhân được chẩn đoán nhiễm HIV/AIDS và được điều trị bằng phác đồ TDF+3TC+DTG theo dõi đủ 24 tuần, trong thời gian từ 2/202- đến 6/2021. Phương pháp: nghiên cứu mô tả cắt ngang hồi cứu kết hợp tiến cứu. Kết quả: Cân nặng, BMI và số lượng CD4 tăng có ý nghĩa thống kê (p<
0,05) tại thời điểm sau 24 tuần điều trị. Có 45/61 (73,8%) bệnh nhân đạt mức vi rút ức chế tối đa (dưới ngưỡng phát hiện). Tuân thủ điều trị có liên quan đến kết quả điều trị (OR=2,32 CI95% 0,21-8,643, p<
0,05). Kết luận: Phác đồ thuốc ARV TDF+3TC+DTG có hiệu quả điều trị tốt trên bệnh nhân nhiễm HIV/AIDS (cân nặng, CD4 tăng sau 24 tuần điều trị và vi rút được ức chế đạt tỷ lệ cao). Nhóm bệnh nhân tuân thủ điều trị tốt có khả năng ức chế vi rút ở mức tối đa cao hon 2,32 lần với nhóm tuân thủ điều trị không tốt.

Tạo bộ sưu tập với mã QR